Contemporary outcomes in non‐muscle‐invasive bladder cancer: a large European multicentre study
BJU International · 2025-11 · 136 (5) · 826-834
DOI: 10.1111/bju.16780 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift BJU International, online erschienen am 21.05.2025. Verfasst von Mattia Longoni und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
To report real‐world rates of non‐muscle‐invasive bladder cancer (NMIBC) recurrence and progression within a European multicentre cohort with detailed information on intravesical instillation courses, as contemporary data on oncological outcomes in NMIBC are limited. Patients and methods A total of 1918 patients with NMIBC treated with transurethral resection of bladder tumour (TURBT) were retrospectively identified from six tertiary‐referral European centres (2015–2022). Patients were stratified according to European Association of Urology 2021 criteria into low‐ (LR), intermediate‐ (IR), high‐ (HR) and very high‐risk (VHR) categories. Cumulative incidence plots and multivariable competing risks regression models addressing 5‐year rates of high‐grade (HG) recurrence and progression were fitted. Sensitivity analyses focused on patients receiving intravesical instillations and tested for the effect of adequate course (Bacillus Calmette‐Guérin: five or more induction + two or more maintenance instillations; mitomycin C: complete induction + ≥11 maintenance instillations).
Results
Of all NMIBC patients identified, 467 (24.3%) were LR vs 582 (30.3%) IR vs 739 (38.5%) HR vs 130 (6.8%) VHR. The median (interquartile range) follow‐up after TURBT was 26 (12–46) months. The 5‐year HG recurrence rates were 7.2% in LR vs 17.3% in IR vs 26.7% in HR vs 30.9% in VHR patients, resulting in a three‐, five‐ and seven‐fold higher risk of IR, HR and VHR, respectively, relative to LR (all P < 0.001). The 5‐year progression rates were 3.9% in LR vs 5.2% in IR vs 13.6% in HR vs 31.6% in VHR patients, resulting in a six‐ and nine‐fold higher risk for HR and VHR, respectively, relative to LR (all P < 0.001). In all, 1001 (52.2%) patients underwent intravesical instillations. Those receiving adequate instillation course (244/1001 [24.3%]) had lower HG‐recurrence (hazard ratio 0.3, P < 0.001) and progression (hazard ratio 0.2, P = 0.001) risk.
Conclusions
Patients with HR/VHR NMIBC face significantly higher HG recurrence and progression risks. While tailored treatment strategies are needed, adherence to adequate instillation course remains crucial for optimising oncological outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
- Vita-Salute San Raffaele University, Milan, Italy.
- Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Centre, Montréal, Québec, Canada.
- Department of Urology, IRCCS 'Regina Elena' National Cancer Institute, Rome, Italy.
- Urology Unit, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy.
- Department of Urology, Claude Huriez Hospital, Lille, France.
ORCID-Profile: Mattia Longoni, Mario De Angelis, Giovanni Tremolada, Giuseppe Simone, Riccardo Mastroianni, Chiara Lonati, Stefania Zamboni, José Daniel Subiela, Aleksander Ślusarczyk, Francesco Soria, Francesco Montorsi, Andrea Salonia, Marco Moschini
Zitieren
APA
Longoni, M., Scilipoti, P., De Angelis, M., Zaurito, P., Tremolada, G., Santangelo, A., Simone, G., Mastroianni, R., Lonati, C., Zamboni, S., Suardi, N., Marcq, G., Szostek, A., Caño Velasco, J., Puentedura, A. L., Subiela, J. D., Durán, P. D. O., Ślusarczyk, A., Karakiewicz, P. I., …, & European Association of Urology ‐ Young Academic Urologists (EAU‐YAU), Urothelial Carcinoma Working Group (2025). Contemporary outcomes in non‐muscle‐invasive bladder cancer: a large European multicentre study. BJU International, 136(5), 826-834. https://doi.org/10.1111/bju.16780
Vancouver
Longoni M, Scilipoti P, De Angelis M, Zaurito P, Tremolada G, Santangelo A, et al. Contemporary outcomes in non‐muscle‐invasive bladder cancer: a large European multicentre study. BJU International. 2025;136(5):826-834. doi:10.1111/bju.16780
BibTeX
@article{Longoni2025,
author = {Longoni, Mattia and Scilipoti, Pietro and De Angelis, Mario and Zaurito, Paolo and Tremolada, Giovanni and Santangelo, Alfonso and Simone, Giuseppe and Mastroianni, Riccardo and Lonati, Chiara and Zamboni, Stefania and Suardi, Nazareno and Marcq, Gautier and Szostek, Aleksandra and Caño Velasco, Jorge and Puentedura, Alfonso Lafuente and Subiela, José Daniel and Durán, Pedro Del Olmo and Ślusarczyk, Aleksander and Karakiewicz, Pierre I and Pradere, Benjamin and Soria, Francesco and Gontero, Paolo and Rouprêt, Morgan and Montorsi, Francesco and Salonia, Andrea and Briganti, Alberto and Moschini, Marco and European Association of Urology ‐ Young Academic Urologists (EAU‐YAU), Urothelial Carcinoma Working Group, European Association of Urology ‐ Young Academic Urologists (EAU‐YAU), Urothelial Carcinoma Working Group},
title = {Contemporary outcomes in non‐muscle‐invasive bladder cancer: a large European multicentre study},
journal = {BJU International},
year = {2025},
volume = {136},
number = {5},
pages = {826--834},
doi = {10.1111/bju.16780}
}
EUVIMED